Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 20/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 19/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 19/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 12/20 | 1.00 |
| ▸ | NCOR2 | Q9Y618 | 9/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.77 |
| ▸ | UBA1 | P22314 | 1/20 | 0.73 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.73 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Largazole Thiol SCHEMBL15195503 | 1.00 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6HDAC8 | |
| Largazole Thiol SCHEMBL7994520 | 1.00 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6HDAC8 | |
| Largazole Thiol SCHEMBL31267135 | 1.00 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6HDAC8 | |
| Largazole Thiol SCHEMBL8040245 | 1.00 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6HDAC8 | |
| Largazole Thiol SCHEMBL15827016 | 1.00 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL15195510 | 0.95 | HDAC3 (0.90) | HDAC3HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL17263837 | 0.95 | HDAC3 (0.90) | HDAC3HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL13453227 | 0.95 | HDAC3 (0.90) | HDAC3HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL12651856 | 0.93 | HDAC3 (0.88) | HDAC3HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL12611184 | 0.93 | HDAC3 (0.88) | HDAC3HDAC1HDAC2HDAC6HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017538-A1 | THIOESTER PRODRUGS OF MACROCYCLES AS INHIBITORS OF HISTONE DEACETYLASES | ONKURE, INC. (US) | 2022-01-20 | — | — | US | disclosed |
| US-11203602-B2 | Thioester prodrugs of macrocycles as inhibitors of histone deacetylases | ONKURE, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20200317693-A1 | THIOESTER PRODRUGS OF MACROCYCLES AS INHIBITORS OF HISTONE DEACETYLASES | ONKURE, INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20190290621-A1 | COMPOSITIONS AND METHODS FOR TREATING HIV-1 LATENCY | WASHINGTON UNIVERSITY | 2019-09-26 | — | — | US | disclosed |
| US-10421778-B2 | Isoform-selective lysine deacetylase inhibitors | WASHINGTON UNIVERSITY (US) | 2019-09-24 | — | — | US | disclosed |
| WO-2018089592-A1 | COMPOSITIONS AND METHODS FOR TREATING HIV-1 LATENCY | WASHINGTON UNIVERSITY (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2017201278-A1 | THIOESTER PRODRUGS OF MACROCYCLES AS INHIBITORS OF HISTONE DEACETYLASES | ONKURE, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| US-20170035759-A1 | TREATMENT OF PARASITIC DISEASES USING KDAC INHIBITOR COMPOUNDS | WASHINGTON UNIVERSITY (US) | 2017-02-09 | — | — | US | disclosed |
| US-20170035759-A1 | TREATMENT OF PARASITIC DISEASES USING KDAC INHIBITOR COMPOUNDS | WASHINGTON UNIVERSITY (US) | 2017-02-09 | — | — | US | disclosed |
| US-9186402-B2 | Method for preparing largazole analogs and uses thereof | Colorado State University Research University (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150210718-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF TREATMENT | UNIV FLORIDA (US) | 2015-07-30 | — | — | US | disclosed |
| US-8759512-B2 | Methods of preparation of macrocyclic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759512-B2 | Methods of preparation of macrocyclic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8513290-B2 | Method for preparing largazole analogs and uses thereof | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-08-20 | — | — | US | disclosed |
| WO-2013086344-A1 | COMBINATION COMPOSITIONS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2013-06-13 | — | — | WO | disclosed |
| US-8129418-B2 | Macrocyclic compounds and methods of treatment | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129418-B2 | Macrocyclic compounds and methods of treatment | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110123644-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110092697-A1 | METHODS OF PREPARATION OF MACROCYCLIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035759-A1 | TREATMENT OF PARASITIC DISEASES USING KDAC INHIBITOR COMPOUNDS | HSP90B1, TBCA, RPL17 | HDAC3 542/4885HDAC1 443/4885HDAC2 1513/4885 |
| US-11203602-B2 | Thioester prodrugs of macrocycles as inhibitors of histone deacetylases | HDAC11, HDAC1, HDAC10 | HDAC3 4/4885HDAC1 2/4885HDAC2 7/4885 |
| US-20190290621-A1 | COMPOSITIONS AND METHODS FOR TREATING HIV-1 LATENCY | HDAC1, HDAC7, HDAC11 | HDAC3 5/4885HDAC1 1/4885HDAC2 11/4885 |
| US-20220017538-A1 | THIOESTER PRODRUGS OF MACROCYCLES AS INHIBITORS OF HISTONE DEACETYLASES | HDAC11, HDAC1, HDAC10 | HDAC3 4/4885HDAC1 2/4885HDAC2 7/4885 |
| US-20200317693-A1 | THIOESTER PRODRUGS OF MACROCYCLES AS INHIBITORS OF HISTONE DEACETYLASES | HDAC11, HDAC1, HDAC10 | HDAC3 4/4885HDAC1 2/4885HDAC2 7/4885 |
| US-20110092697-A1 | METHODS OF PREPARATION OF MACROCYCLIC COMPOUNDS | MKI67, CCNC, PCNA | HDAC3 713/4885HDAC1 548/4885HDAC2 1632/4885 |
| US-20150210718-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF TREATMENT | HDAC1, HDAC11, HDAC3 | HDAC3 3/4885HDAC1 1/4885HDAC2 9/4885 |
| US-20110123644-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF TREATMENT | HDAC1, HDAC11, HDAC3 | HDAC3 3/4885HDAC1 1/4885HDAC2 9/4885 |
| US-10421778-B2 | Isoform-selective lysine deacetylase inhibitors | DOT1L, KDM1A, HDAC1 | HDAC3 36/4885HDAC1 3/4885HDAC2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.